

Supplemental Table 1. Cumulative features of SLE and SS in anti-SMN+ compared to anti-SMN- MCTD patients

	All patients (n=66)	MCTD anti- SMN + (n=39)	MCTD anti- SMN – (n=27)
SLE features, n (%)			
Fever	23 (35)	14 (36)	9 (33)
Leukopenia	27 (41)	16 (41)	11 (41)
Thrombocytopenia	11 (17)	6 (15)	5 (19)
Autoimmune hemolysis	2 (3)	2 (5)	0 (0)
Neuropsychiatric lupus	3 (5)	1 (3)	2 (7)
Aseptic meningitis	2 (3)	1 (3)	1 (4)
Muco-cutaneous symptoms			
Non-scarring alopecia	24 (36)	13 (33)	11 (41)
Oral ulcers	23 (35)	16 (41)	7 (26)
Subacute or discoid lupus	4 (6)	4 (10)	0 (0)
Acute cutaneous lupus	29 (44)	18 (46)	11 (41)
Cutaneous vasculitis / Livedo	23 (35)	15 (38)	8 (30)
Serositis	34 (52)	21 (54)	13 (48)
Arthritis	61 (92)	35 (90)	26 (96)
Renal involvement	9/65 (14)	6/38 (16)	3 (11)
Positive antiphospholipid antibody	18/51 (35)	12/29 (41)	6/22 (27)
Thromboembolic events	5 (8)	3 (8)	2 (7)
SS features, n (%)			
Xerophthalmia	31/38 (82)	20/25 (80)	11/13 (85)
Xerostomia	34/41 (83)	22/26 (85)	12/15 (80)
Parotid gland swelling	18 (27)	12 (31)	6 (22)
Positive labial salivary gland biopsy	5/6 (83)	1/2 (50)	4/4 (100)
Ocular staining score ≥ 5	7/9 (78)	5/5 (100)	2/4 (50)
Schirmer test <5mm/5min	9/13 (69)	3/5 (60)	6/8 (75)
Unstimulated saliva flow rate <0.1mL/min	8/13 (62)	5/7 (71)	3/6 (50)
Positive anti-SSA antibody	27 (41)	19 (49)	8 (30)
Positive anti-SSB antibody	12 (18)	9 (23)	3 (11)

MCTD: mixed connective tissue disease; RNP: ribonucleoprotein; SLE: systemic lupus erythematosus; SMN: survival of motor neuron; SS: Sjögren syndrome